In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of second allogeneic SCT is often uncertain. In a retrospective analysis, 2632 second allogeneic transplantations carried out for a relapse after the first transplantation were analyzed to define indications and identify predictive factors. Fifteen percent of the patients remained relapse-free until 5 years after the second SCT. Patients with CML had a better survival than patients with other diseases. In a multivariate analysis, factors associated with better survival were low disease burden, longer remission duration after the first transplantation, longer interval between the transplantations, younger age, absence of grade II-IV acute GvHD or chronic GvHD after the first transplantation, and later year of transplantation. The European Society for Blood and Marrow Transplantation risk score predicted the outcome. Using the same donor as in the first transplantation vs another donor had no predictive value for survival. Sibling donor was a favorable predictive factor. In conclusion, second allogeneic SCT offers a reasonable option especially for young patients with a long remission after the first transplantation and a low disease burden. The present findings do not support the usefulness of changing the donor for the second transplantation.
INTRODUCTION
The risk of relapse of a malignant disease after allogeneic hematopoietic stem cell transplantation (SCT) varies greatly depending on the disease and its state, from~10% to more than half of the patients. The outcome after relapse is usually poor. 1, 2 The options of treatment are limited. Donor lymphocyte infusions are generally effective in CML, but less frequently in other diseases. 3 Therefore, a second allogeneic SCT is a treatment option. Second transplantations are, however, more problematic than the first ones. Transplantation-related morbidity and mortality may be increased owing to accumulating toxicity, and the risk of a new relapse is high. The indications and outcome of second transplantations are not well established, and the situation is changing with the development of transplantation strategies, including conditioning regimens, choice of donor and prophylaxis of GvHD.
To study the outcome and predictive factors in second allogeneic SCTs for the treatment of relapse of a malignant disease after the first allogeneic SCT, the European Society for Blood and Marrow Transplantation (EBMT) has performed a retrospective analysis of more than 2600 second transplantations carried out during a 16-year period. The aim was to delineate the risks and results of such transplantations to help defining the indications. In second transplantations, besides the indication, also the choice of donor, the intensity of conditioning and the source of graft are to be considered. This analysis aims at producing means to support these practical decisions.
PATIENTS AND METHODS
The study material consisted of 2632 second allogeneic SCTs carried out for relapse of a malignant disease after the first allogeneic SCT at the EBMT centers during the period of 1994-2009 and reported to the EBMT registry. The data were obtained from the EBMT megafile.
The primary outcomes of interest were overall survival (OS), non-relapse mortality (NRM), relapse/progression, relapse/progression-free survival (RFS) and causes of death. Moreover, we assessed the impact of several predictive factors on the outcomes (Table 1) .
Low disease burden was defined as follows: acute leukemia: any remission; CML: any chronic phase; myelodysplastic syndrome/chronic myelomonocytic leukemia/secondary acute leukemia, multiple myeloma and lymphoma: any complete or partial remission. All other disease states represented advanced disease, with the exception of the category 'other diseases' where disease burden was not defined. The intensity of conditioning (myeloablative/reduced intensity) was classified according to the EBMT definitions 4 as reported by the center. Abbreviations: BM = bone marrow; CMML = chronic myelomonocytic leukemia; EBMT = European Society for Blood and Marrow Transplantation; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; MM = multiple myeloma; pALL = primary acute lymphatic leukemia; pAML = primary acute myeloid leukemia; PBSC = peripheral blood stem cell; RIC = reduced-intensity conditioning; sAL = secondary acute leukemia; SCT = stem cell transplantation. All P-values stem from score tests based on Cox models testing overall differences. NRM has been calculated as a cumulative incidence function in a competing risks setting.
a Data missing or not defined 17%. b Data missing 6%.
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Altogether 150 patients had an autologous SCT in their past history. The largest groups were patients with multiple myeloma (n = 43), non-Hodgkin lymphoma (n = 30), primary AML (n = 25) and Hodgkin's disease (n = 16).
Statistical analysis
OS, NRM, relapse/progression and RFS were calculated from the day of the second allogeneic SCT. For OS, death from any cause was the event of interest; patients alive at the last contact were censored. For RFS, the outcome of interest was new relapse/progression after the second transplantation or death; the patients were censored when they were relapse-free at their last follow-up. The outcomes NRM and relapse/ progression were analyzed in a competing risks framework, they were each estimated by means of cumulative incidence curves. We tested the impact of single factors on the outcome by means of log-rank tests for OS and RFS and Cox-model-based score tests for relapse/progression and NRM (both tests being equivalent in models comparing a single factor).
We performed multivariate (cause-specific) Cox regression modeling to estimate the predictive impact of several baseline factors on OS and NRM. We considered the covariates shown in Table 2 and, in addition, gender match at second transplantation, calendar year of first and second transplantation, and conditioning at first transplantation. We calculated the EBMT risk score at the second transplantation on the basis of the value of its components at this time point. To keep the patients in the analysis who had missing values for one or more components of the EBMT score, we replaced the values of their missing covariates by a crude approximation of the mean value of the respective covariates, so creating non-integer scores for some patients. By a likelihood-ratio-based backstep procedure we selected the most predictive factors; subsequently, we fitted a model with these covariates and the year of the second transplantation again on the full data set to reinclude the patients with missing information only on unselected covariates. Disease classification was used as a stratifying variable to model the assumption that all diseases have different baseline hazards but that the impact of the other covariates is the same. A separate Conditioning at second SCT 
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Cox model was fitted to assess the impact of the updated EBMT risk score at second transplantation on OS (again stratifying on disease) because of the correlation of its components with the risk factors in the first models.
All calculations were performed using PASW Statistics 18 (SPSS). Cumulative incidences were calculated by means of SPSS macros developed by the Department of Medical Statistics and Bioinformatics of the LUMC (Leiden, the Netherlands) on the basis of the hazard estimates from the Cox models.
RESULTS

Overall outcomes
The diseases, disease burden, age, intensity of conditioning, type of donor and source of stem cells are shown in Table 1 . The majority had an advanced disease at the second transplantation. In a little over half of the second transplantations the donor was an HLA-identical sibling, and in a third unrelated. In 73% of the cases the donor was the same in the first and second transplantation.
Forty percent of the patients were alive at 1 year (95% CI 38-42%) and 20% (18-22%) at 5 years ( Figure 1 ). Supplementary Table 1 shows the survivals by the disease. The cumulative incidence of NRM was 33% (95% CI 32-35%) at 1 year and 40% (38-42%) at 5 years. The respective incidences of relapse were 36% (34-38%) and 45% (43-47%). Fifteen percent (14-17%) of the patients were alive and relapse-free at 5 years. Fifty-five percent of the deaths were caused by relapse, 45% by non-relapse causes. The leading principal cause for NRM was infection (15%), followed by GvHD (13%) and organ failure (10%).
In univariate analysis (Table 1) , the patients with CML had a significantly better OS than those with other diseases (Supplementary Figure 1 ). An advanced stage of disease predicted poor outcome. This was seen in all major disease groups (Supplementary Table 2 ). In myeloma such an effect was not observed, possibly reflecting a vague distinction between low disease burden and advanced disease. Patients under 20 years of age fared better than the older ones. A longer remission after the Figure 2 . Impact of the duration of remission after the first SCT on relapse incidence, non-relapse mortality and overall and relapse-free survival.
first transplantation was a favorable predictive factor for survival ( Figure 2 ). The patients with an interval of more than 1 year between the transplantations had a clearly better survival than those with a shorter interval (Figure 3 ). The occurrences of acute or chronic GvHD after the first transplantation were unfavorable predictive factors for OS after the second transplantation. The EBMT risk score at the second and first transplantation had a marked predictive value. Factors that significantly predicted the risk of NRM in univariate analysis were disease burden, age, duration of remission after the first transplantation, interval between the transplantations, occurrence of acute or chronic GvHD after the first transplantation, EBMT risk score, type of donor and source of graft (Table 1) . Patients younger than 20 years had a lower risk of NRM than older patients. The risk was lower if the interval between the transplantations was more than 1 year. Patients who had had acute or chronic GvHD after the first transplantation had an increased risk of NRM. Patients with an HLA-identical sibling donor had a lower risk of NRM compared with the rest of the patients.
The overall proportion of patients treated with second allogeneic transplantation of all patients who had a relapse of malignant disease after the first transplantation remained at 15% throughout the whole study period. In individual diseases, particularly in CML, the use of second transplantations declined because of the development of alternative treatments.
Donor
There was no difference in OS or RFS between transplantations from the same vs another donor (Figure 4 ; Table 1 ). The NRM was slightly lower and the relapse rate slightly higher (non-significant) when the donor was the same as at the first transplantation; these effects compensated each other for OS and RFS as outcomes.
In the second transplantations from a sibling donor, the NRM was lower than in the transplantations from an unrelated donor, whereas there was no significant difference in the relapse rate ( Figure 5 ; Table 1 ). There was a small but significant difference in favor of sibling donors in OS and RFS. In the second transplantations, 90% of the patients with a sibling donor and 47% of those with an unrelated donor at the first transplantation received a graft from the same donor. In multivariate analysis for OS, the type of donor had a statistically significant effect, patients with an unrelated or other family donor faring worse than those with a sibling donor ( Table 2) .
To address the question of whether the occurrence of acute (grade II-IV) or chronic GvHD after the first transplantation should affect the choice of the donor, the outcome of patients with GvHD preceding the second transplantation was analyzed according to the type of donor in the second transplantation. In the transplantations from the original or other donor, the OS at 5 years was 20 and 12%, relapse incidence 44 and 42% and NRM 42 and 48%, respectively (no significant difference).
Conditioning
In univariate analysis (Table 1) there was a borderline significant difference in OS in favor of the patients who received a myeloablative conditioning at the second transplantation compared with those given reduced-intensity conditioning. There was no significant difference in NRM. Neither the intensity of conditioning at the first transplantation nor the combination of the conditionings at the first and second transplantation had any significant predictive value for survival or NRM (Supplementary Table 3 ). In multivariate analysis ( Table 2 ) the intensity of conditioning at the second transplantation had no predictive Figure 3 . Impact of the interval between the two transplantations on relapse incidence, non-relapse mortality and overall and relapse-free survival. Figure 5 . Impact of the type of donor in the second transplantation on relapse incidence, non-relapse mortality and overall and relapse-free survival: HLA-identical sibling/other related/unrelated.
value for survival. However, there was a significantly lower risk of NRM among the patients given reduced-intensity conditioning.
Source of graft
The survival of patients given a bone marrow graft was significantly higher and the incidence of NRM lower compared with patients given a PBSC graft (Table 1) . In multivariate analysis the source of graft did not significantly predict survival or NRM.
Multivariate analysis
In the final multivariate Cox model ( Table 2 ) the following factors remained as significant predictive factors for OS: age, duration of remission after the first transplantation, interval between the transplantations, occurrence of grade II-IV acute GvHD after the first transplantation, occurrence of chronic GvHD after the first transplantation, disease burden, EBMT risk score at the first transplantation and the type of donor. Patients older than 35 years fared worse than younger ones. Also the EBMT risk score at the second transplantation significantly predicted the survival (Table 3) . The factors that significantly predicted NRM were the duration of remission after the first transplantation, acute or chronic GvHD between the first and second transplantation, disease burden, EBMT score at the first transplantation, type of donor and intensity of conditioning. Patients over the age of 35 had higher NRM.
The year of the second transplantation had a small but significant effect on OS, more recent transplantations having a better outcome. There was no significant effect on NRM.
DISCUSSION
The risks and utility of a second allogeneic transplantation carried out for a relapse of malignant disease after the first transplantation depend on many factors, and clear indications for second transplantation have been difficult to establish. The present retrospective study was designed primarily to evaluate transplantrelated problems and mortality as well as factors affecting them. The study covers all malignant hematological diseases treated with second allogeneic SCT for relapse after the first transplantation during the study period and reported to the EBMT. For the analyses, the diseases have been grouped into a few broad categories, as it was not the aim to study the detailed outcome in specific diseases.
After the second transplantation, 40% of the patients survived after 1 year and 20% after 5 years. Fifteen percent were alive and relapse-free at 5 years. In previously published studies on second allogeneic SCT, dealing mainly with myeloid leukemias, 5-year OS of 26-32% and RFS of 25-28% have been presented. [5] [6] [7] [8] Several other studies with shorter follow-up report results predicting 5-year survivals similar to those of the present study.
9-14 The moderate differences observed are likely to represent differences in the patient materials.
When considering a second transplantation, the assessment of the likelihood of successful outcome in the light of prognostic factors is essential. Factors that in previous studies have consistently been shown to have prognostic utility for survival are disease status, 6, 8, [10] [11] [12] [13] 15, 16 interval between the first transplantation and relapse 5, 8, [12] [13] [14] 16 and age. [5] [6] [7] [8] 12, 14, 15, 17 A longer interval from the first transplantation to relapse predicts better survival. The length of the remission after which the prognosis has been found clearly better has usually ranged between 6 months and 1 year. 5, 6, 8, [11] [12] [13] 17 Younger patients, especially those under 20 years of age, fare better. The prognostic utility of some other factors, such as donor sex, conditioning regimen and GvHD has been less clear. 5, 6, 8, 12, 15 We also confirmed a significant association between the survival and the disease burden, age of the patient and the time from the first transplantation to relapse. Considering toxicity, the interval between the two transplantations is relevant. 9, 11 In multivariate analysis we saw only a non-significant trend toward lower NRM with a longer interval, but there was a significant correlation between the length of the interval and survival. Second transplantations carried out later than a year from the first one had a clearly better outcome than those with a shorter interval, which is in line with previous observations.
11,18
Patients who experience a relapse after allogeneic SCT and are considered for second transplantation represent highly individual situations as to their disease, comorbidity and burden of toxicity from earlier treatments; therefore, the assessment of the risks of a second transplantation is particularly important. Gratwohl et al. 19, 20 have presented a risk score for the prediction of outcome after allogeneic SCT for hematological malignancies. In the present study this EBMT score predicted highly significantly the OS and NRM. Rezvani et al. 21 reported in their study on second transplantations in 124 patients who had failed a previous transplantation procedure (approximately half allogeneic, half autologous) that the EBMT risk score significantly predicted the outcome, whereas in the study of Christopeit et al. 13 this score had no significant predictive value for survival.
There was no significant difference in the survival between the transplantations from the original donor and those from another donor, as also observed in previous studies. 7, 8, 12, 13, 16, 22 The survival was marginally, though statistically significantly, better in the transplantations from a sibling donor compared with those from an unrelated donor. Christopeit et al. 13 also found that the outcome was better with a sibling donor. In theory, changing the donor or choosing an unrelated donor instead of a sibling might be logical in an effort to utilize optimally the graftversus-malignancy effect after relapse following the first transplantation. 13, 23 Our findings tend to support this concept. There was a (non-significant) trend to a lower risk of relapse when another donor was used instead of the original one. However, this was counterbalanced by a trend to a lower risk of NRM when using the original donor, leading to a similar OS and RFS in both approaches. Among the patients with GvHD after the first transplantation, the outcomes were similar with the original and other donor. Appreciating the obvious weaknesses of this univariate analysis, the findings do not suggest that the occurrence of GvHD after the first transplantation should affect the choice of donor. Overall, the findings of this study do not support the need to change the donor in the second transplantation or to use an unrelated donor instead of a sibling donor. 
Second allogeneic transplantation for malignancy T Ruutu et al
The intensity of conditioning in the second or in the preceding first transplantation did not show independent predictive impact on survival after the second transplantation, though NRM was significantly lower if reduced-intensity conditioning was given in the second transplantation, observations in line with those of Savani. 16 Bosi et al. 6 found that the patients given TBI in the second conditioning had better OS and leukemia-free survival than those given other conditioning, whereas Eapen et al. 7 observed a higher incidence of relapse in reduced-intensity conditioning transplantations but no difference in OS. The present study suggests that the cumulative toxicity of two conditionings does not have a crucial role in the outcome of the second transplantation and that myeloablative conditioning can, in selected cases, be feasible and indicated at the second transplantation. However, the present findings of the impact of the conditioning have to be interpreted with caution. The spectrum of conditioning regimens is wide, and the EBMT definitions of the intensity may, in some cases, leave space for different interpretations in the centers.
In univariate analysis, the patients given a bone marrow graft had a better survival than those given stem cells from the peripheral blood, caused by lower NRM and lower relapse rate. However, in multivariate analysis the source of graft had no significant predictive value for survival or NRM. Transplantations with PBSC grafts are generally associated with a higher incidence of chronic GvHD, which could be expected to associate with more potent graft-versus-malignancy effect and possibly higher NRM. These expectations were not supported by the present findings. Bosi et al. 6 also found a lower relapse rate in transplantations with bone marrow graft, and the leukemia-free survival was better than in transplantations with PBSC grafts. Guardiola et al. 22 and Shaw et al. 12 did not see any difference in survival between transplantations using these two types of grafts. The present findings seem to indicate that bone marrow is at least as good a graft as PBSC in second transplantations. This may be useful information in view of the more problematic long-term adverse effects, particularly chronic GvHD, when PBSC grafts are used.
The present study is, to our knowledge, the largest material of second SCTs reported, but it has obvious limitations. The spectrum of diseases and their states is wide, and no effort was made to study different diseases in detail. As the factors leading to the decision of a second transplantation instead of non-transplant treatment in a given patient could not be sufficiently clarified from the data available in the registry, an obvious selection bias prevented any meaningful comparisons between the outcomes of second transplantations vs other treatments. Particularly, a comparison with donor lymphocyte infusions, also utilizing the graft-versus-malignancy effect, would have been of interest. Comorbidity scores were available only for a small minority of the patients. The main focus of the study was on the feasibility and toxicity of second allogeneic SCTs. In this kind of heterogeneous patient material there may have been unidentified confounding factors, and therefore the interpretation of the findings has to be cautious. A central aim of the study was to try to find support for practical decisions about the donor, conditioning regimen and source of graft in second transplantations. Appreciating the limitations of the analyses we feel that useful information was produced of these practical aspects to contribute to guidelines of how to carry out a second transplantation. The main recommendations based on the present findings are the following:
Second allogeneic transplantation for a relapse of malignant disease after the first allogeneic transplantation should be considered as a treatment option when the disease burden is low. Preferably, the duration of remission after the first transplantation should be at least 4 months and the interval between the transplantations at least 1 year. Individual judgment, including comorbidity and the EBMT score, is important. Changing the donor of the first transplantation does not improve the outcome. The intensity of the conditioning in the first transplantation does not limit the choice of conditioning for the second transplantation. Bone marrow or PBSC graft can be used, with a similar outcome.
In conclusion, we found that patient groups with a considerable likelihood of long-term survival after second allogeneic transplantation can be defined. Factors associated with favorable outcome were identified, and these predictive factors, together with the evaluation of the general health and comorbidity of the patient, should be used when assessing the likely outcome and indication for a second transplantation.
